On a relative basis, the stock has outperformed the S&P 500 by 3.31% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1% in the last 1 week, and is up 7.83% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 6.08% and the 50-Day Moving Average is 4.45%.
Amicus Therapeutics (NASDAQ:FOLD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.72 and $5.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.09. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.06, notching a gain of 6.50% for the day. The total traded volume was 2,231,364 . The stock had closed at $5.69 on the previous day.
The company Insiders own 8.3% of Amicus Therapeutics shares according to the proxy statements. In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc, Rosenberg Ellen had purchased shares worth of $115,050 in a transaction dated on June 2, 2016. A total of 15,000 shares were purchased at a price of $7.67 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.